| Document |
Document Title |
|
WO/2008/141980A1 |
The invention relates to substituted amino-thiourea compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to the use of the substituted ami...
|
|
WO/2008/142155A2 |
The present invention concerns a method for preparing C-6 phosphorylated D- aldohexoses and C-6 phosphorylated D-aldohexose derivatives, new C-6 phosphorylated D-aldohexoses derivatives and uses thereof. The method comprises incubating p...
|
|
WO/2008/120093A1 |
The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I), as defined in the specification. The invention is also directed to compositions con...
|
|
WO/2008/116321A1 |
This invention relates to compositions of one or more compounds that incorporate one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties, or one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties and on...
|
|
WO/2008/110308A2 |
Cyclohexanedione compounds, and derivatives thereof, which are substituted in 5-position, are suitable for use as herbicides.
|
|
WO/2008/110307A1 |
Cyclohexanedione compounds of Formula (I) wherein R1 is methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, halomethyl, haloethyl, halogen, vinyl, ethynyl, methoxy, ethoxy, halomethoxy or haloethoxy, R2 and R3 are, independently hydrogen, ...
|
|
WO/2008/109591A1 |
Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.
|
|
WO/2008/090640A1 |
Disclosed are: an oxime compound represented by the general formula (1); a photosensitive composition for which the oxime compound is used as a photopolymerization initiator; a method for producing a color filter by using the photosensit...
|
|
WO/2008/072726A1 |
Disclosed is a 1-phenyl 1-thio-D-glucitol compound having the formula (I) or the like, a pharmaceutically acceptable salt thereof, a hydrate of the compound or the pharmaceutically acceptable salt, or a pharmaceutical agent comprising th...
|
|
WO/2008/061029A1 |
Compounds of formula (I) and pharmaceutically acceptable salt thereof, which are modulators of secreted frizzled related protein-1, are disclosed. The compounds, and compositions containing the compounds, can be used to treat various dis...
|
|
WO/2008/057120A1 |
One embodiment of the invention uses thioxanthone compounds containing a choline or choline analogue moiety, such as CCcompound1 or [3-(3,4-Dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxyprop
yl]trimethyl-ammonium chloride, to reduce or...
|
|
WO/2008/052444A1 |
The present invention provides compounds of formula (I) with a six-membered heterocyclic ring, pharmaceutically acceptable salts, solvates or geometrical isomers thereof, and pharmaceutical compositions comprising the said compounds, whe...
|
|
WO/2008/042688A2 |
Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.
|
|
WO/2008/035737A1 |
Disclosed is a 4-nitrobenzoyl derivative represented by the formula [I] or a salt thereof. Also disclosed is a herbicide for a rice plant, which comprises the derivative or the salt as an active ingredient. (I) wherein R1 represents a ha...
|
|
WO/2008/032665A1 |
Disclosed is a compound represented by the formula (1) or a salt thereof, which has excellent inhibitory activity on the production of prostaglandin E2 and is useful as an active ingredient for a pharmaceutical agent having reduced adver...
|
|
WO/2008/022938A1 |
The present invention relates to compounds of the general Formula (I) wherein (A) is a 5 or 6-membered aromatic or heteroaromatic ring; R1 is cycloalkyl or is aryl or heteroaryl, wherein at least one ring is aromatic in nature, unsubstit...
|
|
WO/2008/024963A1 |
Disclosed are compounds and pharmaceutically acceptable salts of Formula (I) wherein A, Q1, Q2, Q3, R3, R4, R5, R0, m, and p are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related ...
|
|
WO/2008/013321A1 |
Novel compounds of formula (A) or a pharmaceutically acceptable salt thereof: wherein symbols are as defined in claims, which are useful as SGLT inhibitors and for treatment of diabetes and related diseases.
|
|
WO/2008/009741A1 |
The present invention relates to novel chromene or thiochromene carboxamide derivatives, the preparation of same, pharmaceutical compositions of same and the use of same as dopamine D3 ligands as a medicament for central nervous system d...
|
|
WO/2008/006836A1 |
A process for the preparation of oxygen-, thio- and nitrogen-ring containing compounds comprising reacting a compound selected from the compounds of formula (I): or the compounds of formula (II): in which R1, R2, R3, R4 = F, Br, C1, CN, ...
|
|
WO/2008/000407A1 |
The invention relates to compounds of the formula (I), in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as in...
|
|
WO/2008/002614A2 |
Disclosed herein are pseudoazulenyl nitrone compounds of general structural formula: (I) or formula (II) and methods of using these compounds to trap free radicals and to treat, prevent, or ameliorate various diseases associated with fre...
|
|
WO/2008/001864A1 |
A C-phenyl 1-thioglucitol compound represented by the formula (I), a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the pharmaceutically acceptable salt. (I) wherein X represents a hydrogen atom or a C1-6 alkyl...
|
|
WO/2007/147879A1 |
The present invention relates to substituted 1,3-diphenylpropane derivatives, to the pharmaceutical compositions containing them and to the therapeutic uses thereof, in particular in the fields of human and animal health.
|
|
WO/2007/093621A1 |
The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicamen...
|
|
WO/2007/092935A1 |
Novel, UV radiation hydroxyalkylaminoalkylthioxanthone photoinitiators are disclosed having a hydroxyalkylaminoalkyl group, which can be in the third conjugated ring at the ortho or meta positions thereof. The hydroxyalkylaminoalkyl grou...
|
|
WO/2007/084595A2 |
This invention discloses novel gamma secretase inhibitors of the formula: R2and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl r...
|
|
WO/2007/080947A1 |
Disclosed is a compound represented by the following general formula (1). (1) In the formula, A and B independently represent a substituted or unsubstituted heterocyclic group or a substituted or unsubstituted condensed polycyclic hydroc...
|
|
WO/2007/063928A1 |
Disclosed is an orally administrable therapeutic or preventive agent for diabetes having few side effects. Also disclosed is a novel compound which is useful as such a therapeutic or preventive agent for diabetes. Specifically disclosed ...
|
|
WO/2007/032818A2 |
A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]e
thanaminium i...
|
|
WO/2007/026377A2 |
A process of preparation of Vilsmeier-Haack reagent is provided where di (trichloromethyl) carbonate reacts with N,N-dimethylformamide to form a Vilsmeier reagent, which can be used efficiently for chlorination of sucrose-6-acetate or su...
|
|
WO/2007/013689A1 |
A compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt or prodrug thereof. The compound, salt and prodrug unexpectedly have excellent GPR40 receptor agonistic activity, and also have ex...
|
|
WO/2006/132442A1 |
Disclosed are a compound represented by the general formula (I): (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the like; and others. The compound or pharmaceutically acceptable...
|
|
WO/2006/125688A1 |
The invention relates to benzoyl-substituted serine amides of formula (I), in which the variables R1 to R11 are defined as cited in the description and to their salts that can be used for agricultural purposes. The invention also relates...
|
|
WO/2006/122771A2 |
The invention relates to substituted benzo-condensed cyclohexanone derivatives, to a method for the production thereof, to medicaments containing said derivatives and to the use of the inventive compounds for producing medicaments.
|
|
WO/2006/121922A1 |
Monoamine re-uptake inhibitors and more specifically serotonin and noradrenaline re-uptake inhibitors are disclosed that have utility in the treatment of disorders of the central or peripheral nervous system in both men and women. The co...
|
|
WO/2006/120444A1 |
The invention provides a compound comprising a xanthone or thiaxanthone sensitising moiety, capable of coordinating to a lanthanide ion by the nitrogen atom of an integral pyridyl group or a related group able to bind a lanthanide ion.
|
|
WO/2006/082010A1 |
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein R1, R2, R2ยด, R3, R4, R5 and X are as defined in the specification and claims. These compounds, and the pharmaceutical compos...
|
|
WO/2006/073197A1 |
It is intended to provide a 1-thio-D-glucitol compound represented by the following formula which shows an effect of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt thereof or a hydrate thereof; and a drug containing...
|
|
WO/2006/065686A2 |
The present invention is concerned with certain novel spiro substituted heterocyclic ring derivatives. These compounds may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenase. They ...
|
|
WO/2006/059345A2 |
A process for the preparation of acetylenic retinoid, ethyl-6-[2- (4,4- dimethylthiochroman-6-yl)ethynyl]nicotinate, a compound of formula 1,comprising, (a) cyclizing phenyl-3-methylbut-2-enylsulfide, a compound of formula 6, in presence...
|
|
WO/2006/051137A1 |
The invention relates to a compound having formula (I) wherein n is 0, 1 or 2, R1 is a linear or branched alkyl group, R2 is selected from among a substituted or non-substituted alkyl group, a substituted or non-substituted aryl group, a...
|
|
WO/2006/040644A2 |
The invention relates to processes for the preparation of substituted thiochroman derivatives of Formula (I), wherein R2 is hydrogen or lower alkyl; R1 is hydrogen, halogen, a leaving group or a group of Formula (II), wherein A is phenyl...
|
|
WO/2006/032893A2 |
The present invention provides a compound of the formula: (IIa); having a reactive functional group M, capable of reacting with a biopolymer, BP, having at least one group capable of reacting with M to form a covalent linkage, to provide...
|
|
WO/2006/034004A2 |
The present invention is directed to a process for preparing certain cysteine protease inhibitors.
|
|
WO/2006/011669A1 |
Novel cinnamic acid-related compounds and salts thereof which are useful as drugs, specifically, compounds represented by the general formula [1] and salts thereof: [1] wherein A is a six-membered hydrocarbon ring or a six-membered heter...
|
|
WO/2006/012135A1 |
Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a sub...
|
|
WO/2006/011047A1 |
This in rention relates to a method for separating enantiomers of a substituted 2-tr:ifluoromethyl-2H-chromene-3-carboxylic acid or ester, a substituted 2-triifluoromethyl-1,2-dihydro-quinoline-3-carboxylic acid or ester, a substituted 2...
|
|
WO/2006/010095A2 |
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a colletion of diseases, disorders, and conditions associated with abnormal depositio...
|
|
WO/2005/123713A1 |
A process for the preparation of a disubstituted acetylene bearing heteroaromatic and heterobicyclic groups of formula I is provided wherein X is S, O, or NR1 wherein R1 is hydrogen or a C1-C6 straight or branched alkyl group; R is hydro...
|
